BioCentury | May 13, 2020
Product Development

Gilead secures global access to remdesivir via generic manufacturing deals

The first manufacturing deals for Gilead’s remdesivir, plus a series of grants for institutions across Europe to develop COVID-19 diagnostics and therapeutics, highlight the importance of global collaboration to tackle the pandemic. Gilead Sciences Inc....
BioCentury | Jan 29, 2020
Distillery Therapeutics

WWTR1-AXL-ABL2 axis inhibition for brain metastases in lung cancer

DISEASE CATEGORY: Cancer INDICATION: Lung cancer Blocking a signaling loop comprised of the transcription factor WWTR1 and the tyrosine kinases AXL and ABL2 could treat metastatic lung cancer. AXL and ABL2 signal between each other,...
BC Innovations | Nov 18, 2019
Distillery Therapeutics

Tyrosine kinase inhibitors for the treatment of pemphigus

DISEASE CATEGORY: Autoimmune disease INDICATION: Pemphigus Tyrosine kinase inhibitors including the dual BCR-ABL/c-Kit inhibitor imatinib could treat pemphigus, an autoimmune blistering disorder. Pemphigus is caused by antibodies against the keratinocyte adhesion molecule DSG3. Imatinib reduced...
BC Extra | Oct 28, 2019
Financial News

After Hong Kong IPO lull, local demand lifts Ascentage offering

Robust local demand helped Ascentage to price its IPO at the top of its proposed range and its shares to rise out of the gate in the second offering after a four-month lapse in listings...
BioCentury | Aug 15, 2019
Finance

Deciphera’s $400M follow-on adds firepower on strength of GIST readout

Outsized investor demand continues unabated for stocks of companies with late stage clinical success stories, as evidenced by Deciphera’s ability to double the size of its follow-on to $400 million with little to no haircut...
BC Extra | Jul 3, 2019
Preclinical News

Controlling CAR T toxicity with BMS's Sprycel

Bristol-Myers Squibb’s leukemia drug Sprycel could stop CAR T associated cytokine release syndrome at the root without the need for engineered control features like off-switches. One of the main limitations of CAR T cell therapy...
BioCentury | Jun 14, 2019
Product Development

Despite senior management shake-up, Novartis’ pipeline is primed to deliver

A string of departures at Novartis AG and strategic shifts by new CEO Vasant Narasimhan have produced a fairly thorough makeover of the executive committee he inherited in 2018. The team gains a pipeline that...
BC Innovations | May 15, 2019
Distillery Therapeutics

Inhibiting PIM2 sensitizes CML to Gleevec

DISEASE CATEGORY: Cancer INDICATION: Chronic myelogenous leukemia (CML) Patient sample, cell culture and mouse studies suggest inhibiting PIM2 could sensitize CML to the dual BCR-ABL/c-Kit inhibitor Gleevec imatinib. In CML patients, levels of PIM2 mRNA...
BC Week In Review | Feb 15, 2019
Clinical News

EC approves BMS's Sprycel for pediatric ALL

The European Commission approved Sprycel dasatinib from Bristol-Myers Squibb Co. (NYSE:BMY) in combination with chemotherapy to treat pediatric patients with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). The approval covers both tablet and...
BC Week In Review | Jan 18, 2019
Company News

MD Anderson collaborating with Ascentage, Nanobiotix on clinical testing of cancer assets

The University of Texas MD Anderson Cancer Center unveiled two new partnerships with China's Ascentage Pharma Group International (Suzhou, China) and France's Nanobiotix S.A. (Euronext:NANO) for clinical testing of their respective cancer assets. MD Anderson's...
Items per page:
1 - 10 of 443